Cardio Diagnostics Holdings, Inc. CDIO PHARMA
Company Overview
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, such as concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Why Investors Should Care
Revenue has grown at a 101.4% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $14.82K (-57.5% YoY); net profit $-6.50M.
- Trailing 12 Months Year-on-year growth — revenue -28.3%.
- 5-Year Trend Long-term compounding — revenue CAGR 101.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 101.40% |
| 1 Year: | -28.30% |
Stock Price Performance
| 1 Year: | -48.69% |
| 6 Months: | -59.67% |
| 3 Months: | -1.51% |
| 1 Month: | +9.50% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)54.94 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 101.4% over 5 years.
CONS
- Trading 70.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CDIO Cardio Diagnostics Holdings, Inc. PHARMA | 1.96 | -0.68 | $5.80M | 0.00% | -90.54% | -75.44% | 101.40% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 1.73K | 10.03K | 15.93K | 7.87K | 6.58K | 940 | 7.47K | 2.85K | 2.68K |
| Operating Income | -227.09K | -786.96K | -1.15M | -1.70M | -2.55M | -1.44M | -4.16M | -1.28M | -1.41M | -1.63M | -1.68M | -1.71M | -1.78M |
| Net Income | -290.06K | -842.00K | -1.15M | -1.03M | -4.02M | -1.93M | -4.16M | -1.29M | -1.41M | -1.64M | -1.68M | -1.71M | -1.79M |
| Diluted EPS | -0.07 | -0.16 | -0.17 | -0.11 | -0.39 | -0.16 | -5.93 | -1.71 | -1.73 | -0.97 | -0.97 | -0.98 | -0.63 |
| R&D Expense | 1.13K | 5.04K | 3.19K | 86.67K | 12.32K | 38.71K | 10.84K | 7.28K | 5.25K | 118.78K | 163.10K | 189.05K | 129.78K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 901 | 950 | 17.07K | 34.89K | 14.82K |
| Operating Income | -620.45K | -4.55M | -7.24M | -8.37M | -6.48M |
| Net Income | -620.45K | -4.66M | -8.38M | -8.38M | -6.50M |
| Diluted EPS | -0.53 | -1.51 | -0.66 | -9.35 | -3.71 |
| R&D Expense | 31.47K | 40.45K | 145.18K | 227.97K | 641.21K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 1.10M | 6.25M | 4.46M | 10.62M | 7.77M |
| Total Equity | 60.37K | 1.07M | 4.30M | 2.96M | 9.56M | 6.97M |
| Cash & Equivalents | - | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | - | 33.88K | 1.95M | 1.50M | 1.06M | 793.06K |
| Current Liabilities | - | 124.43K | 1.95M | 841.14K | 631.70K | 604.84K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.09M | -5.67M | -4.99M | -5.73M |
| Investing Cash Flow | - | -368.00K | -794.29K | -404.19K | -419.31K |
| Financing Cash Flow | - | 9.06M | 3.63M | 11.94M | 3.43M |
| Capital Expenditure | - | -76.15K | -794.29K | -404.19K | -419.31K |
| Free Cash Flow | - | -5.17M | -6.47M | -5.40M | -6.15M |
| Net Change in Cash | - | 3.60M | -2.83M | 6.54M | -2.72M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | -68,862.2% | -478,784.3% | -42,440.4% | -23,977.9% | -43,737.5% |
| Net Margin % | -68,862.2% | -490,630.0% | -49,087.8% | -24,028.2% | -43,832.5% |
| ROE % | -58.1% | -108.4% | -283.2% | -87.7% | -93.2% |
| ROCE % | -63.5% | -105.7% | -200.0% | -83.8% | -90.5% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Renaissance Technologies, LLC | 1.66% | 49.20K | $99.38K |
| 2 | Blackrock Inc. | 1.17% | 34.71K | $70.11K |
| 3 | Geode Capital Management, LLC | 0.89% | 26.23K | $52.99K |
| 4 | Vanguard Capital Management LLC | 0.68% | 20.16K | $40.71K |
| 5 | Citadel Advisors Llc | 0.64% | 19.07K | $38.52K |
| 6 | Xtx Topco Ltd | 0.54% | 16.09K | $32.51K |
| 7 | Jane Street Group, LLC | 0.40% | 11.93K | $24.10K |
| 8 | State Street Corporation | 0.34% | 10.10K | $20.40K |
| 9 | Vanguard Fiduciary Trust Co | 0.10% | 2.82K | $5.70K |
| 10 | Tower Research Capital LLC (TRC) | 0.06% | 1.81K | $3.65K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CDIO
Cardio Diagnostics opens Iowa lab to take heart tests from sample to results - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPcW1pVjFJNkpUVmlpSF9iWTNlZ0VDeVM2eXFjT094S3A5Q2Nfb1FhNDNVYk13OVliZGRnd0JlSlE2OHRiVlZyR0dKbnkxSXJLQktfQW9QWGM5WDl0TjhjUXFXaUFLMHJ0YkJWUWlDdFJhN3NNSm0wM2dCUzZJV0RfbFp2d0dSRi01eC1zNH…
Insider Sale: Senior VP and CDIO of $ATI Sells 16,500 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOMlZ0UlFPMkFsZEZRTjVfSkdRY1ZUcHZTSDZxYk9GWjZTZ2FJTGtMYURuWG5BNXVmcV9SRml3U2pkUzNrZ2xtalZRTElqdURGZ0Jnc2tiZUZ6UHBqbTA3RmptNjhxOEtsSng4VV9MUFI1ZElTTmRrOExnXzhCbVh1OVJETjRGUXIxZHdSaV…
CDIO - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTFBvakZOZFlEc19YTm94cGhyLVJOenFvUnJZWmp4dzlpS1JPYnVOX0wxN2d5dTFjZEk1TmN1T2MycFNhLWdvZEE?oc=5" target="_blank">CDIO</a> <font color="#6f6f6f">Finviz</font>…
CDIO|Cardio Diagnostics Holdings Inc|Price:1.860|Chg%:+0.030 - TradingKey
<a href="https://news.google.com/rss/articles/CBMibkFVX3lxTE9YRmNPSmdQa2Y5YV92SWdXTVJleDF4V0xwSG5vR2lzanJJTGVHblhxX0JTWUc4Z3hCX3VUQnU1b1cxMnpBOEhzd195YXpDSE1rWDlDeVEyejlOTF9hWWF6S2lCVlZ6dWw5N0huRURR?oc=5" target="_blank">CDIO|Cardio Diagnos…
CDIO Should I Buy - Intellectia AI
<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE9mVF80Q1B5MVNRYmxjek1kX19rNS04ZVdMOXQtZG5Ebnd1UnZXQUZSaWp3OW9vZ1NybG9kRWNRODgycEk0Unh5RGc0YTd5dUMtMkZVY3Q0ZG5WWHJLWWc?oc=5" target="_blank">CDIO Should I Buy</a> <font c…
CDIO Shares Gain Momentum with AI-Powered Cardiac Innovations Announcement - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxORDdjOUFQUVZBLWhSMGIxOEhFUDZ4bUwtRlFOWDMxWkdDM2tyX3JpTnNScjNKNU8wNmlJbldVUUxudEtoZ21fMS1OZlI3VEdMRE5zNVhnelBaSWlPNmc1VTZsTFFaYThrYXhkcldRSjVVZmhyZmFDSXpfc0pTejM5Ql82WVlfUmQ0NGlpOU…
CDIO — Frequently Asked Questions
What is the current share price of Cardio Diagnostics Holdings, Inc. (CDIO)?
As of 2026-09-19 21:16 PDT, Cardio Diagnostics Holdings, Inc. (CDIO) trades at $1.96 on NasdaqCM. Its 52-week range is $1.05 to $6.55.
What is the market capitalisation of CDIO?
Cardio Diagnostics Holdings, Inc. (CDIO) has a market capitalisation of $5.80M on NasdaqCM.
What is the P/E ratio of CDIO?
CDIO trades at a trailing price-to-earnings (P/E) ratio of -0.68. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.83.
What is the return on equity (ROE) of CDIO?
CDIO has a return on equity (ROE) of -75.44%. Its return on capital employed (ROCE) is -90.54%.
Is CDIO a good stock to buy?
This page provides a data-driven analysis of Cardio Diagnostics Holdings, Inc. (CDIO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.